CA2773210C - Derivatives of n-hydroxybenzamide for treating hiv infections - Google Patents

Derivatives of n-hydroxybenzamide for treating hiv infections Download PDF

Info

Publication number
CA2773210C
CA2773210C CA2773210A CA2773210A CA2773210C CA 2773210 C CA2773210 C CA 2773210C CA 2773210 A CA2773210 A CA 2773210A CA 2773210 A CA2773210 A CA 2773210A CA 2773210 C CA2773210 C CA 2773210C
Authority
CA
Canada
Prior art keywords
inhibitors
compound according
hiv
day
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2773210A
Other languages
English (en)
French (fr)
Other versions
CA2773210A1 (en
Inventor
Charles Dinarello
Gianluca Fossati
Paolo Mascagni
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Italfarmaco SpA
Original Assignee
Italfarmaco SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Italfarmaco SpA filed Critical Italfarmaco SpA
Publication of CA2773210A1 publication Critical patent/CA2773210A1/en
Application granted granted Critical
Publication of CA2773210C publication Critical patent/CA2773210C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2773210A 2009-10-23 2010-09-14 Derivatives of n-hydroxybenzamide for treating hiv infections Expired - Fee Related CA2773210C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITMI2009A001837A IT1396915B1 (it) 2009-10-23 2009-10-23 Dietil-[6-(4-idrossicarbamoil-fenil-carbamoilossimetil)-naftalen-2-il-metil]-ammonio cloruro ed altri derivati della n-idrossi-benzammide per l'uso nel trattamento di infezioni da hiv.
ITMI2009A001837 2009-10-23
PCT/IB2010/054139 WO2011048514A1 (en) 2009-10-23 2010-09-14 Derivatives of n-hydroxybenzamide for treating hiv infections

Publications (2)

Publication Number Publication Date
CA2773210A1 CA2773210A1 (en) 2011-04-28
CA2773210C true CA2773210C (en) 2017-01-03

Family

ID=42153811

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2773210A Expired - Fee Related CA2773210C (en) 2009-10-23 2010-09-14 Derivatives of n-hydroxybenzamide for treating hiv infections

Country Status (10)

Country Link
US (1) US8637702B2 (https=)
EP (1) EP2490682A1 (https=)
JP (1) JP5746196B2 (https=)
KR (1) KR101687644B1 (https=)
CN (1) CN102548551A (https=)
BR (1) BR112012008780A2 (https=)
CA (1) CA2773210C (https=)
IN (1) IN2012DN03387A (https=)
IT (1) IT1396915B1 (https=)
WO (1) WO2011048514A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6272773B2 (ja) * 2011-11-29 2018-01-31 ナンジン アルゲン ファルマ カンパニー リミテッドＮａｎｊｉｎｇ Ａｌｌｇｅｎ Ｐｈａｒｍａ Ｃｏ． Ｌｔｄ． Ｈｄａｃ６阻害剤・抗腫瘍剤用複素環アミド化合物
CN107007580A (zh) 2012-02-03 2017-08-04 意大发马克股份公司 用于治疗肌肉萎缩症的化合物
IT201600074606A1 (it) * 2016-07-18 2018-01-18 Italfarmaco Spa New benzo-N-hydroxy amide compounds having antitumor activity
US11149082B2 (en) 2016-10-17 2021-10-19 University Of Maryland, College Park Multispecific antibodies targeting human immunodeficiency virus and methods of using the same
IT201900003281A1 (it) * 2019-03-06 2020-09-06 Chemi Spa Processo per preparare {6-[(dietilammino)metil]naftalen-2-il}metil [4-(idrossicarbamoil)fenil]carbammato ad elevata purezza
WO2022088047A1 (zh) * 2020-10-30 2022-05-05 中国科学院深圳先进技术研究院 Itf2357在制备预防和治疗冠状病毒的药物中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1283637B1 (it) 1996-05-14 1998-04-23 Italfarmaco Spa Composti ad attivita' antinfiammatoria ed immunosoppressiva
ITMI20030025A1 (it) 2003-01-10 2004-07-11 Italfarmaco Spa Derivati dell'acido idrossammico ad attivita' antinfiammatoria.
ITMI20030063A1 (it) 2003-01-17 2004-07-18 Italfarmaco Spa Cloridrato monoidrato dell'estere (6-dietilamminometil-naftalen-2-il)metilico dell'acido (4-idrossicarbammoil-fenil)carbammico.
JP2007529548A (ja) * 2004-03-18 2007-10-25 サマリタン，ファーマスーティカルス，インク． 抗ｈｉｖベンズアミド化合物およびベンゾアート化合物
ITMI20041347A1 (it) * 2004-07-05 2004-10-05 Italfarmaco Spa Derivati di alfa-amminoacidi ad attivita'antiinfiammatoria
US20100324034A1 (en) 2007-02-08 2010-12-23 Hazuda Daria J Methods of Using SAHA for Treating HIV Infection

Also Published As

Publication number Publication date
CN102548551A (zh) 2012-07-04
ITMI20091837A1 (it) 2011-04-23
KR20120083356A (ko) 2012-07-25
IT1396915B1 (it) 2012-12-20
KR101687644B1 (ko) 2016-12-19
US8637702B2 (en) 2014-01-28
JP2013508349A (ja) 2013-03-07
JP5746196B2 (ja) 2015-07-08
IN2012DN03387A (https=) 2015-10-23
US20120203014A1 (en) 2012-08-09
WO2011048514A1 (en) 2011-04-28
CA2773210A1 (en) 2011-04-28
BR112012008780A2 (pt) 2020-12-01
EP2490682A1 (en) 2012-08-29

Similar Documents

Publication Publication Date Title
US20240390375A1 (en) Methods and compositions for treating viral or virally-induced conditions
CA2773210C (en) Derivatives of n-hydroxybenzamide for treating hiv infections
US8247613B2 (en) Methods and compositions for the synergistic activation of latent HIV
Barbaro et al. Highly active antiretroviral therapy: current state of the art, new agents and their pharmacological interactions useful for improving therapeutic outcome
Matalon et al. The histone deacetylase inhibitor ITF2357 decreases surface CXCR4 and CCR5 expression on CD4+ T-cells and monocytes and is superior to valproic acid for latent HIV-1 expression in vitro
JP2016519166A (ja) Ｈｉｖ感染症を処置するための方法および組成物
Su et al. An update on the emerging approaches for histone deacetylase (HDAC) inhibitor drug discovery and future perspectives
US20060009527A1 (en) Method of treating TRX mediated diseases
US20190145960A1 (en) Compositions, systems and methods for gene expression noise drug screening and uses thereof
WO2009007673A2 (en) Combination for use in the treatment of atherosclerosis comprising a mast cell inhibitor and a ppar gamma agonist
US20230087766A1 (en) Methods of reactivating latent human immunodeficiency virus and related compositions
ES2394984T3 (es) Nueva combinación para uso en el tratamiento de trastornos inflamatorios
US9956260B1 (en) Treatment of HIV-1 infection and AIDS
Giannakopoulou et al. Scaffold hybridization strategy towards potent hydroxamate-based inhibitors of Flaviviridae viruses and Trypanosoma species
KR20110096028A (ko) 잠복성 hiv 감염 세포에서 hiv-1 프로바이러스를 재활성화시키는 히스톤 디아세틸라제 억제제
WO2009007674A2 (en) Combination for use in the treatment of atherosclerosis comprising a mast cell inhibitor and ramatroban or seratrodast
US10633363B2 (en) EPAC1 activators as HIV latency reversal agents (LRA)
US10975059B2 (en) Small molecule BRD4 modulators for HIV epigenetic regulation
CA2808492A1 (en) Antifungal agents and uses thereof
Norman Therapeutic approaches to respiratory diseases excluding asthma: Trends from the patent literature 1997-2000

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20150526

MKLA Lapsed

Effective date: 20220914